---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-065959"
form_type: "8-K/A"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-05-26T10:43:50+00:00"
generated_at: "2026-05-26T10:45:05.007062+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity

## Summary
- Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
- Company has 45 days (until July 3, 2026) to submit a plan to regain compliance.
- Plan hinges on stockholder approval to convert Series A Preferred Stock into common equity.
- If plan is rejected or compliance not regained within extension, Nasdaq may delist RNAZ.
- Failure to obtain approval by Dec 31, 2026 could trigger redemption of Series A Preferred at fair value.

## SEC filing metadata
- accession: 0001104659-26-065959
- form_type: 8-K/A
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-05-26T10:43:50+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/0001104659-26-065959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/tm2615597d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-065959
- JSON: https://secwatch.observer/filing/0001104659-26-065959.json
- Plain text: https://secwatch.observer/filing/0001104659-26-065959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.